Our Bond registers resale of 34.07M shares

Our Bond, Inc. registers the resale of up to 34,073,681 shares of common stock by registered stockholders in connection with its Nasdaq Global Market direct listing.

Rhea-AI Filing Summary

Our Bond, Inc. registers the resale of up to 34,073,681 shares of common stock by registered stockholders in connection with its Nasdaq Global Market direct listing.

This Supplement discloses an amendment to a Warrant held by Ascent Partners Fund LLC: the Warrant originally covered 16,000,000 shares at an exercise price of $12.35, with 15,991,902 shares currently purchasable. By March 1, 2026, the company reduced the exercise price for 12,000,000 of those shares in three tranches to $2.25, $2.75 and $3.25 for 90 days, after which the price reverts to $12.35.

Insights

Capital Markets Analyst

Warrant repricing creates temporary low‑cost exercise windows for a large tranche of potential shares.

The Amendment reduces exercise prices for 12,000,000 warrant shares in three discrete tranches for 90 days, permitting Ascent to acquire shares at materially lower per‑share prices during that period. The underlying warrant still covers 15,991,902 purchasable shares as stated.

Practical effects depend on Ascent's exercise decisions and any subsequent resale; cash‑flow treatment is not described in this excerpt and timing reverts to original price after the temporary periods.

Corporate Finance Advisor

The amendment may create short‑term dilution potential but is explicitly time‑limited and reversible.

The repricing applies only for 90 days to specified share tranches—4,500,000, 3,750,000, and 3,750,000—and then reverts to $12.35. The filing does not state whether proceeds from any exercises go to the issuer or selling holders.

Subsequent filings or exercises will clarify actual dilution and proceeds; investor impact depends on Ascent's actions during the reduced‑price windows.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Our Bond, Inc.'s (OBAI) registered offering amount?

The prospectus registers the resale of 34,073,681 shares of common stock. This is the aggregate number the Supplement states for resale by Registered Stockholders in connection with the Nasdaq direct listing.

How many warrant shares remain purchasable under the amended Warrant?

The filing states 15,991,902 shares remain purchasable under the Warrant. The Amendment adjusts exercise prices for 12,000,000 of those shares for 90 days.

What exercise price changes were made to the Ascent warrant?

Exercise prices were reduced for 12,000,000 shares to $2.25, $2.75, and $3.25 for 90 days. After that, the price reverts to $12.35.

Who holds the amended Warrant disclosed in the Supplement?

The amended Warrant is held by Ascent Partners Fund LLC. The Supplement identifies Ascent as the holder and discloses the Amendment executed on March 1, 2026.

Does the Supplement state who receives proceeds from any warrant exercises?

The Supplement does not state proceeds treatment. The excerpt does not specify whether exercise proceeds are received by the company or another party.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 06:06 AM Learn about SEC filing dates

PROSPECTUS SUPPLEMENT Dated March 2, 2026 (To Prospectus Dated January 30, 2026) Filed pursuant to Rule 424(b)(5) Registration No. 333-290750

Our Bond, Inc.

Up to 34,073,681 Shares of Common Stock
to be Sold by Registered Stockholders

This prospectus supplement (the “Supplement”) modifies, supersedes and supplements certain information contained in, and should be read in conjunction with, our Prospectus filed with the SEC dated January 30, 2026 (the “Prospectus”), related to the registration of the resale of up to 34,073,681 shares of our common stock, par value $0.0001 per share, by our stockholders identified in the Prospectus (the “Registered Stockholders”) in connection with our direct listing on the Global Market tier of the Nasdaq Stock Market LLC.

This Supplement is not complete without, and may not be delivered or used except in connection with, the Prospectus.

Our shares of common stock are listed on the Nasdaq Global Market under the symbol “OBAI.”

The information contained in this Supplement modifies and supersedes, in part, the information in the Prospectus. Any information that is modified or superseded in the Prospectus shall not be deemed to constitute a part of the Prospectus, except as modified or superseded by this Supplement. We may amend or supplement the Prospectus from time to time by filing amendments or supplements as required. You should read the entire Prospectus, and any amendments or supplements carefully before you make an investment decision.

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 7 of the Prospectus and in documents incorporated by reference into the Prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this Supplement, or the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

FORWARD-LOOKING STATEMENTS

You should carefully consider the risk factors set forth in the Prospectus, as well as the other information contained in or incorporated by reference into this Supplement and the Prospectus. This Supplement and the Prospectus and documents incorporated therein by reference contain forward-looking statements regarding events, conditions, and financial trends that may affect our plan of operation, business strategy, operating results, and financial position. You are cautioned that any forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Actual results may differ materially from those included within the forward-looking statements as a result of various factors. Cautionary statements in the “Risk Factors” section of the Prospectus and in documents incorporated by reference into the Prospectus identify important risks and uncertainties affecting our future, which could cause actual results to differ materially from the forward-looking statements made or included in this Supplement and the Prospectus.

WARRANT AMENDMENT

This Supplement is being filed to disclose an amendment to certain warrants to purchase shares of our common stock held by Ascent Partners Fund LLC (“Ascent”).

On March 1, 2026, we entered into Amendment No. 1 (the “Amendment”) to the terms of one of our outstanding Warrants to Purchase Shares of Common Stock issued October 27, 2025 (the “Warrant”). As originally issued, the Warrant provided for the purchase of up to 16,000,000 shares of our common stock at an exercise price of $12.35 per share, with an expiration date of July 27, 2026. Currently, 15,991,902 shares of common stock remain purchasable under the Warrant.

Under the Amendment, the exercise price of the Warrants for a total of 12,000,000 shares of common stock has been reduced as follows:

●	The exercise price for 4,500,000 shares of common stock purchasable under the Warrant has been reduced to $2.25 per share for a period of ninety (90) days;
●	The exercise price for 3,750,000 shares of common stock purchasable under the Warrant has been reduced to $2.75 per share for a period of ninety (90) days; and
●	The exercise price for 3,750,000 shares of common stock purchasable under the Warrant has been reduced to $3.25 per share for a period of ninety (90) days.

Following the expiration of the reduced exercise price periods described above, the exercise price for the Warrants will revert to the original price of $12.35 per share as set forth in the original Warrants.

The date of this Prospectus Supplement is March 2, 2026